Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Certara, Inc. - Common Stock (NQ:CERT)

14.15 +0.62 (+4.58%)
Streaming Delayed Price Updated: 4:00 PM EDT, Apr 17, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Certara, Inc. - Common Stock

< Previous 1 2 Next >
Certara to Report Fourth Quarter and Full Year 2023 Financial Results on February 29th, 2024 and Participate in the Barclays 26th Annual Global Healthcare Conference
From Certara
Via GlobeNewswire
Certara Acquires Applied BioMath Expanding Its Biosimulation Portfolio to Industrialize New Capabilities for Optimal Dosing for Novel Therapies
Combined organization establishes the life sciences industry’s largest quantitative systems pharmacology (QSP) center of excellence contributing to faster and more effective medicine development. 
From Certara
Via GlobeNewswire
Certara introduces Simcyp™ Biopharmaceutics software to increase efficiency of novel and generic drug formulation & development
Simcyp Biopharmaceutics helps drug developers replace costly clinical bioequivalence studies and optimize formulations for complex therapies 
From Certara
Via GlobeNewswire
Certara Reports Third Quarter 2023 Financial Results
Reiterates Full Year 2023 Financial Guidance 
From Certara
Via GlobeNewswire
Certara to Report Third Quarter 2023 Financial Results on November 8th, 2023, and participate in the Stephens Annual Investment Conference
From Certara
Via GlobeNewswire
Certara Announces 300th Regulatory Submission Milestone Using its Technology-enabled Services and Software
Dedicated team of global regulatory experts delivers submissions in increasingly shorter timelines 
From Certara
Via GlobeNewswire
Certara to Participate in Upcoming Investor Conferences
From Certara
Via GlobeNewswire
Certara Simcyp™ Group Awarded Two New Grants from US FDA
Programs focus on use of physiologically-based pharmacokinetic (PBPK) modeling for demonstrating virtual bioequivalence and predicting drug absorption of topical formulations 
From Certara
Via GlobeNewswire
Certara Reports Second Quarter 2023 Financial Results
Provides Update to Full Year 2023 Financial Guidance 
From Certara
Via GlobeNewswire
Certara to Report Second Quarter 2023 Financial Results on August 9th, 2023
From Certara
Via GlobeNewswire
Certara to Participate in the Jefferies Global Healthcare Conference
From Certara
Via GlobeNewswire
Certara Reports First Quarter 2023 Financial Results
Reiterates 2023 Financial Guidance 
From Certara
Via GlobeNewswire
Certara Customers Received 90 Percent of US FDA Novel Drug Approvals for 9th Consecutive Year
Asserts Certara’s leadership in advancing the development and approval of new drugs for patients 
From Certara
Via GlobeNewswire
Certara to Report First Quarter 2023 Financial Results on May 8th, 2023 and Participate in the BofA Securities 2023 Healthcare Conference
From Certara
Via GlobeNewswire
Are These 3 Small Momentum Stocks Setting Up Big Gains?
MINISO, PDF Solutions, and Certara are small stocks with strong price momentum. It’s not unusual for small stocks to show more price momentum than larger peers. 
Via MarketBeat
A.I. Coming to Certara’s D360 Scientific Informatics Software
New deep learning capabilities will provide data and insight to inform property prioritization, novel structure design and literature-based analyses. 
From Certara
Via GlobeNewswire
Certara announces the release of Simcyp™ PBPK Simulator Version 22, expanding ability to simulate untested scenarios for new patient and therapeutic types
Simcyp Simulator has been utilized to inform more than 300 label claims for 90+ novel drugs in lieu of conducting clinical studies 
From Certara
Via GlobeNewswire
Certara Reports Fourth Quarter and Full Year 2022 Financial Results
Annual Revenue Grows 17% on a Reported Basis and 20% at Constant Currency 
From Certara
Via GlobeNewswire
Certara Announces Transition Plan for Chief Financial Officer
From Certara
Via GlobeNewswire
Certara to Participate in the Barclays Global Healthcare Conference
From Certara
Via GlobeNewswire
Certara to Report Fourth Quarter and Full Year 2022 Financial Results on March 1st, 2023
From Certara
Via GlobeNewswire
Certara Acquires Vyasa, an Artificial Intelligence Company that Delivers Predictions to Accelerate Scientific Innovation
Certara improves software capabilities by expanding into deep learning and data fabric 
From Certara
Via GlobeNewswire
Certara Announces the Completion of Arsenal Capital Partners’ Investment and the Appointment of David Spaight to the Board of Directors
Arsenal closed the previously announced $449M stock purchase from funds controlled by EQT Private Equity 
From Certara
Via GlobeNewswire
Certara Reports Third Quarter 2022 Financial Results
Biosimulation software and services fuel third quarter growth 
From Certara
Via GlobeNewswire
Arsenal Capital Partners Increases Investment in Global Biosimulation Leader Certara with $449M Stock Purchase
Arsenal will acquire approximately 30M shares at $15 per share from funds controlled by EQT Private Equity and agrees to two-year lock-up on sale of shares 
From Certara
Via GlobeNewswire
Certara to Participate in Upcoming Investor Conferences
From Certara
Via GlobeNewswire
Japan’s Pharmaceuticals and Medical Devices Agency (PMDA) Renews Licenses of Certara’s Software for Evaluating Regulatory Submissions
The PMDA enters 9th consecutive year of using Certara’s software 
From Certara
Via GlobeNewswire
Certara to Report Third Quarter 2022 Financial Results on November 7th, 2022
From Certara
Via GlobeNewswire
Certara to Present at the BofA Securities 2021 Virtual Health Care Conference
From Certara, Inc.
Via Business Wire
Certara to Report Preliminary First Quarter 2021 Financial Results on May 6, 2021
From Certara, Inc.
Via Business Wire
< Previous 1 2 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.